PharmaShots | Incisive News in 3 Shots

Subscribe Now

ESMO ASIA Virtual Congress 2020

Innovent Reports Results of Tyvyt + Byvasda (biosimilar- bevacizumab) in P-lll ORIENT-32 Study as 1L Treatment for HCC

Innovent Reports Results of Tyvyt + Byvasda (biosimilar- bevacizumab) in P-lll ORIENT-32 Study as 1L Treatment for HCC

November 23, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us